ArticleFrontiers in oncology2021

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer.

Xiao-Hong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.